{"filings":[{"id":609804,"accession_number":"0001104659-26-065730","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-05-22T20:15:46+00:00","items":["5.02"],"status":"ready","headline":"Zura Bio director Someit Sidhu resigns effective May 21; no disagreement cited","event_type":"leadership","confidence":"high","bullets":["Someit Sidhu resigned from Zura Bio's board on May 20, effective May 21, 2026.","Resignation is not due to any disagreement with company operations, policies, or practices.","No replacement director announced or named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96300,"accession_number":"0001628280-26-031701","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zura Bio Q1 net loss $24.2M ($0.22/sh); advancing tibulizumab Phase 2 trials","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.2M ($0.22 per share) vs. $17.4M ($0.19) in Q1 2025.","R&D expenses $14.7M, up from $10.5M, driven by tibulizumab Phase 2 programs.","Cash $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028.","Phase 2 TibuSHIELD (HS) on track for topline data Q4 2026; TibuSURE (SSc) data expected H1 2027.","Completed $144M public offering in February 2026; appointed new CEO and two board members."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96299,"accession_number":"0001104659-26-047784","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Eric Hyllengren departs; Marlyn Mathew named principal accounting/financial officer","event_type":"leadership","confidence":"high","bullets":["CFO Eric Hyllengren separated from Zura Bio on April 20, 2026; separation not related to financial/operating results.","Hyllengren receives 3 months base salary severance and COBRA reimbursement up to 6 months.","Marlyn Mathew, VP Finance and Accounting since June 2022, appointed principal accounting and financial officer.","Mathew's base salary set at $366,415 per Board approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110078,"accession_number":"0001104659-26-032077","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.","Cash and equivalents $109.4M at Dec 31, 2025; Feb 2026 offering raised ~$144M gross.","R&D expenses $42.1M, up 73% YoY, driven by Phase 2 tibulizumab programs.","Phase 2 TibuSHIELD (HS) topline data expected Q4 2026; TibuSURE (SSc) data H1 2027.","Appointed Sandeep Kulkarni as CEO in Jan 2026; added two board members in Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110077,"accession_number":"0001104659-26-025520","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio provides updated corporate presentation; no financial results disclosed","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation furnished as Exhibit 99.1 for use at conferences and investor meetings.","Presentation available on company website at investors.zurabio.com.","No specific financial, clinical, or operational updates are included in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110076,"accession_number":"0001104659-26-023806","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio presents Phase 2 TibuSURE trial design at SSc World Congress; no data yet","event_type":"other_material","confidence":"high","bullets":["Design of Phase 2 TibuSURE trial evaluating tibulizumab (dual IL-17A/BAFF inhibition) in diffuse cutaneous systemic sclerosis accepted for poster presentation.","Trial enrolls ~80 adults, randomized 1:1 tibulizumab versus placebo for 24 weeks, then 28-week open-label extension.","Primary endpoint is change in modified Rodnan Skin Score at Week 24; topline results expected first half 2027.","No clinical efficacy or safety data will be presented; poster covers rationale and study design only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110075,"accession_number":"0001104659-26-019827","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Zura Bio prices $125M public offering of 18.2M shares at $6.25 and 1.8M pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Offering: 18.2M Class A ordinary shares at $6.25/share, plus 1.8M pre-funded warrants at $6.249 each.","Net proceeds expected ~$134.6M; underwriters' option for 3M additional shares exercised in full.","Preliminary cash and equivalents as of Dec 31, 2025: ~$109.4M.","Total outstanding ordinary shares after offering (excl. pre-funded warrants) ~94.9M.","Offering expected to close Feb 26, 2026; joint bookrunners: Leerink, Piper Sandler, Cantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110069,"accession_number":"0001104659-26-020132","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K/A","filed_at":"2026-02-26T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Zura Bio files 8-K/A to correct legal exhibits; no new business disclosure","event_type":"other","confidence":"high","bullets":["Amendment only restates Exhibits 5.1 (legal opinion) and 23.1 (consent) from Feb 25, 2026 8-K.","Original 8-K covered underwriting agreement and pre-funded warrant offering.","No changes to any financial, operational, or other substantive disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110074,"accession_number":"0001104659-26-018312","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zura Bio appoints Eisner and Nirula to board; Graham resigns","event_type":"leadership","confidence":"high","bullets":["Neil Graham resigned from Zura's board effective Feb 21, 2026; departure not due to any disagreement.","Mark Eisner (Vir Bio CMO) and Ajay Nirula (Recludix Pharma EVP R&D, former Lilly exec) appointed as directors.","Each new director receives $40k annual cash retainer and initial option for up to 51,000 shares (or $200k value).","Board changes come as Zura advances Phase 2 tibulizumab trials in hidradenitis suppurativa and systemic sclerosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110073,"accession_number":"0001104659-26-012935","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio issues updated corporate presentation; no specific new facts in filing text","event_type":"other","confidence":"low","bullets":["Presentation posted as Exhibit 99.1, dated February 11, 2026, for use at conferences and investor meetings.","The filing provides no financial results, guidance changes, or corporate actions.","Full presentation is accessible on the company's website at investors.zurabio.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110072,"accession_number":"0001104659-26-006326","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zura Bio announces CEO resignation and appointment of Sandeep Kulkarni as new CEO","event_type":"leadership","confidence":"high","bullets":["Robert Lisicki resigned as CEO and director effective January 21, 2026, after medical leave since October 2025.","Dr. Sandeep Kulkarni appointed CEO and continues as director; will receive $655,000 base salary and equity awards.","Separation agreement with Lisicki includes $72,000 annualized transition compensation through March 31, 2026.","Parvinder Thiara appointed to board effective January 23, 2026; previously served from 2022 to 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110071,"accession_number":"0001104659-26-002688","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zura Bio expands HS trial to 225 patients; expects Q4 2026 data; cash through 2027","event_type":"other_material","confidence":"high","bullets":["Phase 2 TibuSHIELD trial in HS expanded from 180 to 225 participants; topline data expected Q4 2026.","Phase 2 TibuSURE trial in SSc: topline data anticipated in first half of 2027.","Cash and equivalents sufficient to fund operations through 2027, beyond both data readouts.","Tibulizumab is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110070,"accession_number":"0001104659-26-000209","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","1.02","3.02","8.01","9.01"],"status":"ready","headline":"Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital","event_type":"other_material","confidence":"high","bullets":["Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.","Issued 8,657,402 Class A ordinary shares to Athanor; $7.325M upfront fee and $25M milestone payment on change of control or first regulatory approval.","Athanor receives piggyback registration rights and 2% net sales royalty on tibulizumab (ZB-106) from the Lilly license.","Audit Subcommittee review completed; no financial statement impact or employee misconduct found.","New terms deemed more commercially advantageous; prior agreements voided with broad releases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126636,"accession_number":"0001104659-25-121826","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Arnout Ploos van Amstel resigns from Zura Bio Board effective Dec 11, 2025","event_type":"leadership","confidence":"high","bullets":["Arnout Ploos van Amstel resigned from the Board and Nominating and Governance Committee.","Resignation effective December 11, 2025; no disagreement cited with Company operations.","No replacement director announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126635,"accession_number":"0001104659-25-110789","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zura Bio reports Q3 2025 net loss of $20.0M; cash $139M to fund through 2027","event_type":"earnings","confidence":"high","bullets":["Net loss $20.0M ($0.21/sh) vs $22.9M ($0.26/sh) in Q3 2024; R&D spend rose to $11.9M as Phase 2 trials advanced.","Cash and equivalents $139.0M as of Sep 30, 2025; company expects to fund planned operations through 2027.","Phase 2 trials tibulizumab: TibuSHIELD (HS) topline Q3 2026; TibuSURE (SSc) topline Q4 2026.","G&A expenses decreased to $7.6M from $13.3M, driven by prior-year one-time non-cash share-based comp.","No revenue reported; clinical-stage immunology company with no approved products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126634,"accession_number":"0001104659-25-098546","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO Robert Lisicki takes medical leave; COO Kim Davis appointed interim CEO effective Oct 10","event_type":"leadership","confidence":"high","bullets":["CEO Robert Lisicki informed Zura Bio of a medical leave of absence starting October 10, 2025.","Board appointed Kim Davis (COO, CLO, Corporate Secretary) as interim CEO effective October 10, 2025.","Davis will serve as interim CEO in addition to her current duties as COO, CLO, and Corporate Secretary.","No arrangement, transactions under Item 404(a), or family relationships disclosed related to appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143409,"accession_number":"0001104659-25-095024","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zura Bio adopts Executive Severance Benefit Plan for CEO and named executives","event_type":"other_material","confidence":"high","bullets":["CEO: 12 months base salary on regular termination; 18 months + 150% target bonus on change-in-control termination.","Other named executives: 9 months base salary (regular) or 12 months + 100% target bonus (change-in-control).","Plan effective September 24, 2025; requires signed release agreement for eligibility.","Supersedes any prior severance agreements or arrangements for covered executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143408,"accession_number":"0001104659-25-087286","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio files updated corporate presentation for investor meetings","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation dated September 4, 2025, filed as Exhibit 99.1.","Presentation highlights Zura Bio's dual-pathway biologic candidates in autoimmune/inflammatory diseases.","No specific clinical, financial, or guidance changes disclosed; presentation is a routine update.","Ticker ZURA is the sole identifier; no counterparties mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143407,"accession_number":"0001104659-25-080521","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio to present at Cantor Fitzgerald Global Healthcare Conference Sept 4","event_type":"other","confidence":"high","bullets":["Fireside chat at 2:45 PM ET on Sept 4, 2025 in New York.","Company will also conduct one-on-one investor meetings that day.","Live webcast available in Investors section of Zura Bio website; replay for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143406,"accession_number":"0001104659-25-078142","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zura Bio Q2 2025 net loss $16.0M; cash $154.5M funds through 2027","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $154.5M as of June 30, 2025, expected to fund operations through 2027.","Q2 2025 net loss of $16.0M ($0.17 per share) vs $10.3M ($0.17 per share) in Q2 2024.","R&D expenses rose to $8.7M (up $3.2M YoY) driven by Phase 2 studies for tibulizumab in SSc and HS.","Initiated TibuSHIELD Phase 2 for hidradenitis suppurativa; topline data expected Q3 2026.","Appointed Eric Hyllengren as CFO (July 2025) and Dan Becker, M.D., Ph.D. to Board (May 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143405,"accession_number":"0001104659-25-064427","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zura Bio appoints Eric Hyllengren as CFO; Verender Badial steps down effective July 7, 2025","event_type":"leadership","confidence":"high","bullets":["Eric Hyllengren appointed CFO effective July 7, 2025; previously COO/CFO at Atara Biotherapeutics and 15 years at Amgen.","Verender Badial resigns as CFO, stays as non-executive employee through July 31, 2025 to assist transition.","Badial receives £178,294.92 cash severance, accelerated vesting for 186,561 options; 303,100 options forfeited.","Hyllengren gets $475,000 base salary, 40% target bonus, and option for 672,000 shares vesting over 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161576,"accession_number":"0001104659-25-056205","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio posts updated corporate presentation for Jefferies conference","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation filed as Exhibit 99.1 on June 4, 2025.","Presentation titled 'Advancing Dual-Pathway Biologic Candidates' for Jefferies Global Healthcare Conference.","No specific financial or pipeline milestones disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161575,"accession_number":"0001104659-25-052682","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio to present corporate overview at Jefferies Global Healthcare Conference June 4, 2025","event_type":"other","confidence":"low","bullets":["Senior leadership team will present at Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 PM ET in New York.","Company will also participate in one-on-one investor meetings during the conference.","Live webcast available on Zura Bio website; replay archived for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161574,"accession_number":"0001104659-25-052250","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zura Bio shareholders elect all nine director nominees and ratify auditor at 2025 AGM","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Dan Becker received 32,757,554 for, 36,056 against.","Auditor WithumSmith+Brown, PC ratified for FY 2025 with 44,576,844 for, 36,032 against.","Adjournment proposal not voted on as Proposals 1 and 2 passed with requisite votes.","Meeting held May 21, 2025 with a quorum present; next AGM date to be determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161573,"accession_number":"0001104659-25-050715","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio launches global Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa","event_type":"other_material","confidence":"high","bullets":["TibuSHIELD will enroll ~180 adults with moderate-to-severe HS across US, Canada, and Europe.","Study is 28-week, double-blind, placebo-controlled, with 16-week primary efficacy and 12-week safety follow-up, plus optional OLE.","Primary endpoint: percent change in total abscess and nodule count at Week 16; secondary endpoints include HiSCR50/75.","Topline results for primary endpoint expected in Q3 2026.","Tibulizumab targets both BAFF and IL-17A pathways; still investigational, not FDA-approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161572,"accession_number":"0001104659-25-045865","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zura Bio Q1 net loss $17.4M; cash $170.6M; trial on track","event_type":"earnings","confidence":"high","bullets":["Net loss $17.4M ($0.19/sh) vs $7.7M ($0.02/sh) in Q1 2024; R&D spend $10.5M (+192% YoY).","Cash and equivalents $170.6M; runway expected to fund operations through 2027.","Phase 2 TibuSURE trial for systemic sclerosis continues; HS Phase 2 expected Q2 2025.","Appointed Kate Dingwall as SVP of Development Operations to support clinical execution.","G&A expenses $8.8M, increased $4.0M YoY due to compensation and professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161571,"accession_number":"0001104659-25-036057","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Zura Bio exchanges 6.5M shares for pre-funded warrants at $0.001/share","event_type":"other_material","confidence":"high","bullets":["Venrock surrenders 3.5M shares; AI Biotechnology surrenders 3.0M shares for no consideration.","Company issues pre-funded warrants to purchase same number of shares at $0.001 per share, no expiration.","Post-closing expected shares: 61,874,998 outstanding Class A; 30,384,348 pre-funded warrants.","Warrants exercisable immediately with 9.99% beneficial ownership limitation; exempt under Section 3(a)(9).","No commissions paid; warrants substantially identical to form filed April 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179713,"accession_number":"0001104659-25-027815","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio furnishes updated corporate presentation; no material new details disclosed.","event_type":"other_material","confidence":"low","bullets":["Company provided updated corporate presentation for investor meetings on March 25, 2025.","Presentation filed as Exhibit 99.1 via Item 7.01; no financial or operational updates specified.","No new guidance, pipeline changes, or material events were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179712,"accession_number":"0001104659-25-027504","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.","Net loss improved to $45.4M ($0.60 per share) from $69.2M ($2.09 per share) in 2023.","Initiated Phase 2 TibuSURE trial for tibulizumab in systemic sclerosis (SSc) in Dec 2024; Phase 2 HS trial planned for Q2 2025.","Completed $112.5M private placement in April 2024; also executed warrant exchange and established ATM program in 2024.","Robert Lisicki appointed CEO in April 2024; Kiran Nistala joined as CMO in Jan 2024; Scientific Advisory Board established June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179711,"accession_number":"0001104659-25-016345","cik":1855644,"company_name":"Zura Bio Ltd","ticker":"ZURA","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zura Bio to present at Leerink Partners Global Healthcare Conference on March 11, 2025","event_type":"other","confidence":"high","bullets":["Members of senior leadership will participate in a fireside chat on Tuesday, March 11, 2025 at 1:40 p.m. ET.","Live webcast and replay will be available on the News & Events page of Zura Bio's website for at least 30 days.","Zura Bio is a clinical-stage immunology company developing dual-pathway antibodies for autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}